Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on average 50.3 lb (22.8 kg) while those treated with semaglutide lost 33.1 lb (15 kg), translating to a 47% greater relative weight loss with tirzepatide.
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
Martin Makary, President-elect Trump’s pick for running the Food and Drug Administration, is an executive of the telehealth ...
State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...
In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...
Poison control centers around the country are warning about a rise in calls of patients overdosing on Ozempic.
Canada's health regulator has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback